02628 Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

0 Analyst Rating

Wall Street analysts forecast 02628 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02628 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

0 Hold

0 Sell

Current: 0.000

Low

Averages

High

Current: 0.000

Low

Averages

High

Goldman Sachs

Neutral

maintain

2025-11-10

Reason

Goldman Sachs

Price Target

2025-11-10

maintain

Neutral

Reason

Goldman Sachs adjusted its analyst rating for CHINA LIFE (02628.HK) based on the company's strong performance in its 3Q25 results, particularly noting that its investment income exceeded expectations. This led to a significant increase in their full-year net profit forecast by 69% and a 7% increase in the 2025-27 first-year premium forecasts. Additionally, the positive performance of the bank insurance sales channel and management's optimistic outlook for 2026 contributed to the adjustments. Goldman Sachs also raised its per-share dividend forecasts by 10% due to an expanded investment portfolio and stronger premium inflow, with this year's dividend expected to grow by 23% YoY, surpassing previous estimates. Despite these positive adjustments, the target price was raised from HKD22.5 to HKD24.5, while maintaining a Neutral rating.

CMB International

maintain

$29 -> $31

2025-11-05

Reason

CMB International

Price Target

$29 -> $31

2025-11-05

maintain

Reason

CMB International maintained a Buy rating for China Life due to the company's impressive 3Q25 results, which showed a nearly doubling of net profit to RMB126 billion, representing a 92% year-over-year increase. This strong performance, driven by both insurance service results and investment results, led CMB International to raise its earnings per share (EPS) forecasts for FY2025-27 and revise the FY2025 new business value (NBV) growth forecast to 38%. Additionally, the target price for China Life was increased from HK$29 to HK$31, reflecting confidence in the company's growth trajectory.

Morgan Stanley

maintain

$25.7

2025-10-31

Reason

Morgan Stanley

Price Target

$25.7

2025-10-31

maintain

Reason

The analyst rating for CHINA LIFE (02628.HK) is set at "Overweight" due to several key factors highlighted in the article. Firstly, the company reported the highest earnings growth among its peers in 3Q25, with a remarkable net profit increase of 60.5% for the first nine months of 2025. This performance translates to an annualized return on equity (ROE) of 88.3% for 3Q25 and 39.4% for 9M25, indicating strong profitability. Additionally, the value of new business (VONB) accelerated significantly to 41.8% in 9M25, up from 20.3% in the first half of the year. Morgan Stanley noted that CHINA LIFE outperformed most of its peers across multiple indicators and that the management has a positive outlook for the upcoming year. These factors contributed to the positive analyst rating and the target price of HKD25.7.

UBS

maintain

$29

2025-10-31

Reason

UBS

Price Target

$29

2025-10-31

maintain

Reason

The analyst rating from UBS on CHINA LIFE (02628.HK) is a "Buy" with a target price of HKD29. This positive rating is based on the company's strong performance, highlighted by a 42% year-over-year increase in Value of New Business (VNB) for the first nine months of 2025, which exceeded market expectations. Additionally, the net profit after tax (NPAT) grew by 61% to RMB168 billion, aligning with the mid-range of earlier profit forecasts. The strong VNB growth this year contributes to a more constructive outlook for the company in the upcoming year.

BofA Securities

Buy

upgrade

2025-10-31

Reason

BofA Securities

Price Target

2025-10-31

upgrade

Buy

Reason

The analyst rating for CHINA LIFE (02628.HK) was reiterated as a Buy by BofA Securities due to the company's impressive financial performance, which included a 61% year-over-year increase in net profit for the first three quarters of 2025, reaching RMB167.8 billion. This performance significantly exceeded market expectations. Additionally, the company's quarterly net profit of RMB126.9 billion in Q3 2025 surpassed the previous year's full-year figure, and its investment income rose by 92% year-over-year, benefiting from gains in the A-share market. The total investment return rate of 6.4% was also noted as the highest among its peers, further supporting the positive outlook. Consequently, BofA raised its target price for the stock from HKD25.7 to HKD29.3.

Citi Research

NULL

Buy

upgrade

$27.7

2025-10-20

Reason

Citi Research

Price Target

$27.7

2025-10-20

upgrade

NULL

Buy

Reason

The analyst rating for CHINA LIFE (02628.HK) was upgraded to "Buy" by Citi Research due to a profit alert forecasting a significant increase in net profit for 1-3Q25, projected to rise by 50-70% year-over-year. This growth is attributed to a substantial year-over-year increase in investment returns, a higher allocation to equity investments, an optimized asset allocation structure, and proactive investments in new quality productive sectors. For 3Q25 specifically, net profit is expected to grow by 75-106% year-over-year, despite a high base from the previous year. The target price set by the broker is $27.7.

Valuation Metrics

The current forward P/E ratio for CHINA LIFE (02628.HK) is 7.49, compared to its 5-year average forward P/E of 6.06. For a more detailed relative valuation and DCF analysis to assess CHINA LIFE 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

6.06

Current PE

7.49

Overvalued PE

8.37

Undervalued PE

3.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.20

Current PS

1.69

Overvalued PS

1.40

Undervalued PS

1.00

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

02628 News & Events

Events Timeline

No data

News

4.5

04:12 AMaastocks

<Midday Update> HSI Falls 272 Points; HSTI Declines by 96 Points; BABA Drops More Than 4%; CHINAHONGQIAO, CHINA LIFE, NANSHAN AL INTL, ND PAPER, CMOC Reach New Peaks

4.0

01-06aastocks

<BofAS Analysis> Ratings and Target Prices for Chinese Insurers (Table)

4.0

01-06aastocks

BofAS Identifies Potential for Product Structure Enhancement in Chinese Insurers, Revises Target Prices for the Sector

People Also Watch

Frequently Asked Questions

What is CHINA LIFE (02628) stock price today?

The current price of 02628 is 31.82 USD — it has increased 2.32 % in the last trading day.

What is CHINA LIFE (02628)'s business?

What is the price predicton of 02628 Stock?

Wall Street analysts forecast 02628 stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02628 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is CHINA LIFE (02628)'s revenue for the last quarter?

CHINA LIFE revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is CHINA LIFE (02628)'s earnings per share (EPS) for the last quarter?

CHINA LIFE. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for CHINA LIFE (02628)'s fundamentals?

The market is revising No Change the revenue expectations for 02628 for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by %.

How many employees does CHINA LIFE (02628). have?

CHINA LIFE (02628) has 0 emplpoyees as of January 07 2026.

What is CHINA LIFE (02628) market cap?

Today 02628 has the market capitalization of 0.00 USD.

02628

Overview

Forecast

Valuation

Earnings

02628

Overview

Forecast

Valuation

Earnings

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

02628 News & Events

Events Timeline

No data

News

People Also Watch

Frequently Asked Questions

What is CHINA LIFE (02628) stock price today?

What is CHINA LIFE (02628)'s business?

What is the price predicton of 02628 Stock?

What is CHINA LIFE (02628)'s revenue for the last quarter?

What is CHINA LIFE (02628)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for CHINA LIFE (02628)'s fundamentals?

How many employees does CHINA LIFE (02628). have?

What is CHINA LIFE (02628) market cap?